Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 301

Results For "pharma"

4245 News Found

Govt. planning 10,000 Jan Aushadhi Kendras by March 2024
Policy | January 13, 2023

Govt. planning 10,000 Jan Aushadhi Kendras by March 2024

The implementing agency of PMBJP has invited online applications for opening of new Jan Aushadhi Kendras in 651 districts of different States/UTs


HLL pays Rs. 122.47 crore as dividend to Government of India for FY 21-22
News | January 12, 2023

HLL pays Rs. 122.47 crore as dividend to Government of India for FY 21-22

The company has played an important role in the procurement and distribution of emergency medical supplies supporting the Union Health Ministry for Covid–19 pandemic management


Apollo Genomics Institutes launched at Apollo Hospitals Navi Mumbai
News | January 12, 2023

Apollo Genomics Institutes launched at Apollo Hospitals Navi Mumbai

Launch of Apollo Genomics Institutes would provide genetic counselling, tests, treatment and care for genetic disorders


Merck named one of America’s Most JUST Companies by JUST Capital and CNBC
News | January 11, 2023

Merck named one of America’s Most JUST Companies by JUST Capital and CNBC

The JUST 100 is the only ranking that recognizes companies doing right by all their stakeholders as defined by the American public.


Lupin and Exeltis announce reimbursement approval of NaMuscla in Spain
News | January 10, 2023

Lupin and Exeltis announce reimbursement approval of NaMuscla in Spain

NDM disorders are a group of rare, inherited neuromuscular disorders with an estimated prevalence of 1 case per 100,000 inhabitants in Spain, and are characterized by the inability to relax muscles following voluntary contraction (myotonia)


ProBioGen collaborates with Boehringer Ingelheim on DirectedLuck transposase technology
News | January 10, 2023

ProBioGen collaborates with Boehringer Ingelheim on DirectedLuck transposase technology

The new project further expands the partner's long-term collaboration on new technologies for R&D


Lupin receives approval from USFDA for Fesoterodine Fumarate Extended-Release Tablets
Drug Approval | January 07, 2023

Lupin receives approval from USFDA for Fesoterodine Fumarate Extended-Release Tablets

Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, (RLD Toviaz®) had estimated annual sales of USD 177 million in the U.S. (IQVIA MAT September 2022).


Zydus launches Topiramate Extended-Release Capsules
Drug Approval | January 07, 2023

Zydus launches Topiramate Extended-Release Capsules

Zydus is the first company to receive final approval and launch Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg in the United States.


Alembic receives USFDA final approval for Fesoterodine Fumarate Extended-Release Tablets
Drug Approval | January 07, 2023

Alembic receives USFDA final approval for Fesoterodine Fumarate Extended-Release Tablets

Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, have an estimated market size of US$ 177 million for twelve months ending Sep 2022